Assays Performed Using Lung Biopsy-Derived Tumor Infiltrating
Lymphocytes Show Improved Restoration of T Cell Function Using
Enumeral’s Anti-PD-1 Antibody
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company
focused on discovering and developing novel antibody immunotherapies
that help the immune system fight cancer and other diseases, today
announced important progress in its anti-PD-1 antibody program. Enumeral
researchers have demonstrated greater functional activity of its novel
class of anti-PD-1 antibodies (as measured by restoration of T cell
function in cell-based assays) when compared to conventional anti-PD-1
antibodies that disrupt PD-1 interaction with PD-L1. Enumeral’s
potentially allosteric antibodies block PD-L1-mediated
immunosuppression, but do not disrupt PD-1 interaction with PD-L1.
Enumeral’s researchers measured the ability of anti-PD-1 antibodies to
restore interferon gamma production by tumor infiltrating lymphocytes
(TILs) derived from tumor biopsy specimens obtained from patients
diagnosed with lung cancer. Compared to the use of currently marketed
anti-PD-1 antibodies, experiments with Enumeral’s anti-PD-1 antibody
resulted in approximately 50% to 100% higher interferon gamma production
by the TILs.
“We have accomplished a number of important goals in our recent
experiments, most critical of which was to demonstrate the
differentiated activity of our novel class of anti-PD-1 antibodies,”
said Cokey Nguyen, Ph.D., Enumeral’s Vice President of Research and
Development. “We employed the widely used protocol of pre-administering
CD3 and CD28 to activate the TILs, and yet in certain of the samples we
saw very little baseline T cell function prior to antibody treatment.
Anti-PD-1 blockade was critically needed in concert with TIL activation
to observe enhanced T cell function, underscoring just how
immunosuppressed the tumor microenvironment can be.”
“Our recent progress has confirmed the potential of employing ex vivo
human approaches to measure the function of, and functional responses
elicited by, novel immuno-oncology drug candidates. We believe such
analyses will provide a strong basis for further drug development
decisions, as well as supporting regulatory submission as our programs
advance toward clinical development,” commented Arthur H. Tinkelenberg,
Ph.D., President and Chief Executive Officer of Enumeral.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, TIGIT, VISTA, and others. In developing these
agents, Enumeral’s researchers apply a proprietary immune profiling
technology platform that measures functioning of the human immune system
at the level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
Forward Looking Statements Disclosure
This press release contains certain “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995, as
amended. Such statements reflect current beliefs of Enumeral Biomedical
Holdings, Inc. (“Enumeral”) with respect to future events and involve
known and unknown risks, uncertainties, and other factors affecting
operations, market growth, Enumeral’s stock price, services, products
and licenses. No assurances can be given regarding the achievement of
future results, and although Enumeral believes that the expectations
reflected in these forward-looking statements are based on reasonable
assumptions, actual results may differ from the assumptions underlying
the statements that have been made regarding anticipated events. Factors
that may cause actual results, performance or achievements, or industry
results to differ materially from those contemplated by such
forward-looking statements include, among others, the risks that (a)
Enumeral’s expectations regarding market acceptance of the Company’s
business in general and the Company’s ability to penetrate the antibody
discovery and development fields in particular, as well as the timing of
such acceptance, (b) Enumeral’s ability to attract and retain management
with experience in biotechnology and antibody discovery and similar
emerging technologies, (c) the scope, validity and enforceability of
Enumeral’s and third party intellectual property rights, (d) Enumeral’s
ability to raise capital when needed and on acceptable terms and
conditions, (e) Enumeral’s ability to comply with governmental
regulation, (f) the intensity of competition, (g) changes in the
political and regulatory environment and in business and fiscal
conditions in the United States and overseas and (h) general economic
conditions.
More detailed information about Enumeral and risk factors that may
affect the realization of forward-looking statements, including
forward-looking statements in this press release, is set forth in
Enumeral’s filings with the Securities and Exchange Commission. Enumeral
urges investors and security holders to read those documents free of
charge at the Commission’s website at http://www.sec.gov.
Forward-looking statements speak only as to the date they are made, and
except for any obligation under the U.S. federal securities laws,
Enumeral undertakes no obligation to publicly update any forward-looking
statement as a result of new information, future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151103005434/en/
Copyright Business Wire 2015